South Korea Precision Medicine in Oncology Drug Market Size, Share, and COVID-19 Impact Analysis, By Technology (Genomic Biomarker Testing, Proteomic & molecular biomarker Testing, Companion Diagnostics (CDx), Pharmacogenomics (PGX) in Oncology, and Bioinformatics & Data Analytics Platforms), By Cancer Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Prostate Cancer, Leukemia/Lymphoma, and Other Solid Tumors), By End User/Purchaser (Pharmaceutical & Biotechnology Companies, Diagnostic/Clinical Laboratories, Hospitals and Oncology Clinics, and Research Institutes & Academic Centers), By Application (Drug Discovery & Development, Clinical Diagnostics, and Research Use Only (RUO)), and South Korea Precision Medicine in Oncology Drug Market Insights, Industry Trend, Forecasts to 2035

South Korea Precision Medicine in Oncology Drug Market Insights Forecasts to 2035

• The Market Size is Expected to Grow at a CAGR of around 8.3% from 2025 to 2035
• The South Korea Precision Medicine in Oncology Drug Market Size is Expected to hold a significant share by 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Precision Medicine in Oncology Drug Market Size is anticipated to hold a significant share by 2035, growing at a CAGR of 8.3% from 2025 to 2035. The increasing demand for personalized healthcare solutions, along with the increasing development of innovative oncology drugs, is driving the precision medicine in the oncology drug market in South Korea.  

Market Overview

The South Korea precision medicine in oncology drug market refers to the industry tailoring cancer treatment to an individual’s unique genetic and molecular characteristics, moving away from a “one-size-fits-all” approach by using molecular testing to guide targeted therapies and improving patient outcomes. Precision medicine in oncology includes the use of genomic technologies at the point of care for informing clinical treatment decisions, allowing more accurate and efficient prediction of individualized therapies as per the patient-specific needs. There is a growing focus on early cancer detection and the development of innovative screening technologies in the precision medicine in oncology drug market. personalized medicine targeting specific cancer subtypes and mutations, and enabling more effective and tailored treatments, addressing the unique genetic and molecular profiles of cancer. Integration of technologies like NGS and AI for detailed tumor profiling and acceleration of personalized drug discovery and treatment is escalating the market growth opportunities.

Report Coverage

This research report categorizes the market for the South Korea precision medicine in oncology drug market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea precision medicine in oncology drug market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea precision medicine in oncology drug market.

Driving Factors

The precision medicine in the oncology drug market is primarily driven by factors including the growing cancer incidence and technological advancements like genomic sequencing, companion diagnostics, and AI. The implementation of personalized treatment plans in oncology across hospitals, with an increasing demand for targeted therapies and precision diagnostics, is responsible for driving the precision medicine in oncology drug market. The development of innovative medicinal products for oncology patients to provide better treatment alternatives at potentially lower cost is contributing to promoting market growth. 

Restraining Factors

The increased medicine cost due to increased usage of high-end calculation methods and advanced computing tools is challenging the market. Further, the complexity in the regulatory approval process associated with novel drug products is hampering the market growth.

Market Segmentation

The South Korea precision medicine in oncology drug market share is classified into technology, cancer indication, end user/purchaser, and application.

• The bioinformatics & data analytics platforms segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea precision medicine in oncology drug market is segmented by technology into genomic biomarker testing, proteomic & molecular biomarker testing, companion diagnostics (CDx), pharmacogenomics (PGX) in oncology, and bioinformatics & data analytics platforms. Among these, the bioinformatics & data analytics platforms segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Bioinformatics and data analytics platforms are essential for managing, integrating, and analysing large and complex data in cancer research and clinical management of cancer patients.

• The leukemia/lymphoma segment held the dominant market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea precision medicine in oncology drug market is segmented by cancer indication into lung cancer, breast cancer, colorectal cancer, gastric cancer, prostate cancer, leukemia/lymphoma, and other solid tumors. Among these, the leukemia/lymphoma segment held the dominant market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The increasing sector of precision medicine for individualized treatment on the basis of genetic background is contributing to drive market growth.

•  The hospitals and oncology clinics segment held the dominant market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea precision medicine in oncology drug market is segmented by end user/purchaser into pharmaceutical & biotechnology companies, diagnostic/clinical laboratories, hospitals and oncology clinics, and research institutes & academic centers. Among these, the hospitals and oncology clinics segment held the dominant market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The presence of numerous international malignant treatment facility providers, along with a rise in cancer prevalence and international tourism, is driving the market in the hospitals and oncology clinics segment.

• The drug discovery & development segment held a significant market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea precision medicine in oncology drug market is segmented by application into drug discovery & development, clinical diagnostics, and research use only (RUO). Among these, the drug discovery & development segment held a significant market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Strategic collaborations and continued innovation are allowing the development and delivery of cancer therapeutics and care.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea precision medicine in oncology drug market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• SG Medical
• Seegene Inc.
• Yuhan Corporation
• LSK BioPharma
• LabGenomics
• GC Labs
• Macrogen
• JN Biosciences
• JLK Bio
• 3BIGS
• Others

Recent Developments:

• In August 2025, ImmuneOncia signed a memorandum of understanding (MOU) with IMBDx to accelerate cancer drug and precision medicine development.
• In March 2025, Macrogen, Pharos iBio to co-develop precision companion diagnostics for cancer therapy. Macrogen said it has signed a memorandum of understanding (MoU) with Pharos iBio, an AI-driven new drug development company, to collaborate on the development of companion diagnostics (CDx) aimed at advancing precision medicine.
• In December 2024, Avacta Group is redefining cancer treatment through its proprietary proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Precision Medicine in Oncology Drug Market based on the below-mentioned segments:

South Korea Precision Medicine in Oncology Drug Market, By Technology

• Genomic Biomarker Testing
• Proteomic & molecular biomarker Testing
• Companion Diagnostics (CDx)
• Pharmacogenomics (PGX) in Oncology
• Bioinformatics & Data Analytics Platforms

South Korea Precision Medicine in Oncology Drug Market, By Cancer Indication

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Prostate Cancer
• Leukemia/Lymphoma
• Other Solid Tumors

South Korea Precision Medicine in Oncology Drug Market, By End User/Purchaser

• Pharmaceutical & Biotechnology Companies
• Diagnostic/Clinical Laboratories
• Hospitals and Oncology Clinics
• Research Institutes & Academic Centers

South Korea Precision Medicine in Oncology Drug Market, By Application

• Drug Discovery & Development
• Clinical Diagnostics
• Research Use Only (RUO)